Gitterman Wealth Management LLC increased its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 25.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 961 shares of the conglomerate’s stock after acquiring an additional 196 shares during the period. Gitterman Wealth Management LLC’s holdings in Danaher were worth $221,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently bought and sold shares of DHR. Kovack Advisors Inc. lifted its stake in shares of Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares during the period. Gilbert & Cook Inc. increased its holdings in Danaher by 2.5% in the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after buying an additional 42 shares in the last quarter. Grimes & Company Inc. raised its position in shares of Danaher by 0.6% in the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock worth $1,696,000 after acquiring an additional 43 shares during the period. Harbour Investments Inc. boosted its stake in shares of Danaher by 3.0% during the 3rd quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock worth $426,000 after acquiring an additional 45 shares in the last quarter. Finally, Dakota Community Bank & Trust NA grew its position in shares of Danaher by 16.4% during the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock valued at $73,000 after acquiring an additional 45 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.10% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on DHR
Danaher Stock Up 3.4 %
NYSE DHR opened at $211.09 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The business’s fifty day simple moving average is $220.07 and its 200-day simple moving average is $240.63. The firm has a market cap of $150.87 billion, a PE ratio of 39.98, a P/E/G ratio of 2.66 and a beta of 0.82.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the business posted $2.09 EPS. As a group, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.
Danaher Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.61%. Danaher’s dividend payout ratio (DPR) is 24.24%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- 3 Best Fintech Stocks for a Portfolio Boost
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to trade using analyst ratings
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.